Adding Bevacizumab to Lung Cancer Treatment Results in Modest Overall Survival Benefits, According to Study in JNCCN from Abramson Cancer Center

Thursday, May 23, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Researchers from University of Pennsylvania find adding bevacizumab to carboplatin-pemetrexed was effective in treating non-squamous non-small cell lung cancer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store